Cargando…

The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6

BACKGROUND: The discrepant concordance between biopsy and radical prostatectomy (RP) specimen are well reported. To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanfeng, Gu, Liangyou, Wu, Yongjie, Feng, Dan, Duan, Junyao, Wang, Xiaocong, Huang, Yong, Wu, Shengpan, Chen, Jianwen, Luo, Guangda, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586011/
https://www.ncbi.nlm.nih.gov/pubmed/28874127
http://dx.doi.org/10.1186/s12885-017-3614-9
_version_ 1783261737276932096
author Wang, Hanfeng
Gu, Liangyou
Wu, Yongjie
Feng, Dan
Duan, Junyao
Wang, Xiaocong
Huang, Yong
Wu, Shengpan
Chen, Jianwen
Luo, Guangda
Zhang, Xu
author_facet Wang, Hanfeng
Gu, Liangyou
Wu, Yongjie
Feng, Dan
Duan, Junyao
Wang, Xiaocong
Huang, Yong
Wu, Shengpan
Chen, Jianwen
Luo, Guangda
Zhang, Xu
author_sort Wang, Hanfeng
collection PubMed
description BACKGROUND: The discrepant concordance between biopsy and radical prostatectomy (RP) specimen are well reported. To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific antigen (tPSA) and value of their combination. METHODS: One hundred one patients who underwent physical examinations incidentally found elevated tPSA and subsequently received biopsy with a conclusion of GS ≤ 6 and RP with an interval of 4-6 weeks after biopsy were enrolled. NLR and tPSA were obtained within 15 days prior to biopsy. Logistic regression model was applied appropriately; McNemar tests and AUC model were performed to evaluate differences among tPSA, NLR and their combination and corresponding diagnostic power respectively. RESULTS: The pathological results from RP specimen comprised 61 patients with GS ≤ 6 and 100 patients with GS ≥ 7. Higher tPSA and NLR were significantly associated with patients with actual GS ≥ 7 (All P < 0.05) concurrently. Multivariate logistic regression indicated that tPSA (OR = 1.088, 95% C.I. = 1.029-1.151, P = 0.003) and NLR (OR = 1.807, 95% C.I. = 1.021-3.200, P = 0.042) could be independent predictors for GS groupings. Under cutoff value of 14.09 ng/ml for tPSA and 2.25 for NLR, the sensitivity, specificity and accuracy were 60.0%, 80.3% and 67.7% for tPSA, 42%, 88.5% and 59.6% for NLR, and 71.0%, 75.4% and 72.7% for combination of tPSA and NLR (tPSA + NLR) respectively. The sensitivity of tPSA + NLR was significantly higher in comparison with tPSA (P = 0.001) and NLR (P < 0.001). Except for sensitivity, no significant difference was found between tPSA and NLR in specificity (P = 0.227) and accuracy (P = 0.132). tPSA got the largest AUC with 0.732 (p < 0.001, 95% C.I.: 0.651-0.813). CONCLUSIONS: Serum tPSA and NLR were significantly elevated among GS ≥ 7 PCa concurrently. The combination of tPSA and NLR might have additional benefit to biopsy on discriminating real GS ≥ 7 Pca from biopsy-based GS ≤ 6 PCa. More stratification models and prospectively multicenter studies are necessary.
format Online
Article
Text
id pubmed-5586011
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55860112017-09-06 The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 Wang, Hanfeng Gu, Liangyou Wu, Yongjie Feng, Dan Duan, Junyao Wang, Xiaocong Huang, Yong Wu, Shengpan Chen, Jianwen Luo, Guangda Zhang, Xu BMC Cancer Research Article BACKGROUND: The discrepant concordance between biopsy and radical prostatectomy (RP) specimen are well reported. To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific antigen (tPSA) and value of their combination. METHODS: One hundred one patients who underwent physical examinations incidentally found elevated tPSA and subsequently received biopsy with a conclusion of GS ≤ 6 and RP with an interval of 4-6 weeks after biopsy were enrolled. NLR and tPSA were obtained within 15 days prior to biopsy. Logistic regression model was applied appropriately; McNemar tests and AUC model were performed to evaluate differences among tPSA, NLR and their combination and corresponding diagnostic power respectively. RESULTS: The pathological results from RP specimen comprised 61 patients with GS ≤ 6 and 100 patients with GS ≥ 7. Higher tPSA and NLR were significantly associated with patients with actual GS ≥ 7 (All P < 0.05) concurrently. Multivariate logistic regression indicated that tPSA (OR = 1.088, 95% C.I. = 1.029-1.151, P = 0.003) and NLR (OR = 1.807, 95% C.I. = 1.021-3.200, P = 0.042) could be independent predictors for GS groupings. Under cutoff value of 14.09 ng/ml for tPSA and 2.25 for NLR, the sensitivity, specificity and accuracy were 60.0%, 80.3% and 67.7% for tPSA, 42%, 88.5% and 59.6% for NLR, and 71.0%, 75.4% and 72.7% for combination of tPSA and NLR (tPSA + NLR) respectively. The sensitivity of tPSA + NLR was significantly higher in comparison with tPSA (P = 0.001) and NLR (P < 0.001). Except for sensitivity, no significant difference was found between tPSA and NLR in specificity (P = 0.227) and accuracy (P = 0.132). tPSA got the largest AUC with 0.732 (p < 0.001, 95% C.I.: 0.651-0.813). CONCLUSIONS: Serum tPSA and NLR were significantly elevated among GS ≥ 7 PCa concurrently. The combination of tPSA and NLR might have additional benefit to biopsy on discriminating real GS ≥ 7 Pca from biopsy-based GS ≤ 6 PCa. More stratification models and prospectively multicenter studies are necessary. BioMed Central 2017-09-06 /pmc/articles/PMC5586011/ /pubmed/28874127 http://dx.doi.org/10.1186/s12885-017-3614-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Hanfeng
Gu, Liangyou
Wu, Yongjie
Feng, Dan
Duan, Junyao
Wang, Xiaocong
Huang, Yong
Wu, Shengpan
Chen, Jianwen
Luo, Guangda
Zhang, Xu
The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
title The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
title_full The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
title_fullStr The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
title_full_unstemmed The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
title_short The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
title_sort values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real gleason score ≥ 7 prostate cancer from group of biopsy-based gleason score ≤ 6
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586011/
https://www.ncbi.nlm.nih.gov/pubmed/28874127
http://dx.doi.org/10.1186/s12885-017-3614-9
work_keys_str_mv AT wanghanfeng thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT guliangyou thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wuyongjie thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT fengdan thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT duanjunyao thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wangxiaocong thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT huangyong thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wushengpan thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT chenjianwen thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT luoguangda thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT zhangxu thevaluesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wanghanfeng valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT guliangyou valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wuyongjie valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT fengdan valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT duanjunyao valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wangxiaocong valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT huangyong valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT wushengpan valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT chenjianwen valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT luoguangda valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6
AT zhangxu valuesofneutrophillymphocyteratioandorprostatespecificantigenindiscriminatingrealgleasonscore7prostatecancerfromgroupofbiopsybasedgleasonscore6